How India Exports Capecitabine to the World

In the United States, capecitabine is approved for the treatment of various cancers, including colorectal and breast cancers. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for capecitabine, indicating a competitive generic market. Notably, the high number of Indian exporters (216) underscores India's significant role in supplying capecitabine to the U.S. market. As of March 2026, there are no active FDA import alerts specifically targeting capecitabine, suggesting compliance with U.S. regulatory standards.

In the European Union, capecitabine is authorized for marketing under various brand names and generic formulations. The European Medicines Agency (EMA) has approved multiple capecitabine products, such as Capecitabine Medac, which received marketing authorization on 19 November 2012. Similarly, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and monitoring of capecitabine products within the UK. Manufacturers exporting to these regions must adhere to EU Good Manufacturing Practice (GMP) requirements to ensure product quality and safety.

Capecitabine is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its importance in cancer treatment. The drug is also listed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters across different regions.

In India, capecitabine is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including capecitabine, to ensure affordability. Exporters are required to obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for capecitabine have expired, leading to the availability of generic versions and increased competition in the market. This has resulted in a more accessible and cost-effective treatment option for patients globally.

In April 2025, the NPPA revised the ceiling price for capecitabine, reducing it by 10% to enhance affordability for patients. In June 2025, the EMA approved a new generic formulation of capecitabine, further increasing market competition in the EU. In September 2025, the FDA issued updated guidance on the bioequivalence requirements for capecitabine generics, aiming to streamline the approval process for new entrants. In November 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of capecitabine as a critical cancer treatment. In January 2026, the Indian government implemented stricter export regulations for pharmaceuticals, including capecitabine, to ensure the quality of exported medicines.

These developments reflect ongoing efforts by regulatory authorities to balance the availability, affordability, and quality of capecitabine in the global market.

Capecitabine, an antineoplastic agent, is primarily manufactured in India, which has established itself as a global hub for Active Pharmaceutical Ingredient (API) production. However, the production of APIs like capecitabine often relies on Key Starting Materials (KSMs) sourced from China. China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in this sector. This heavy reliance on Chinese KSMs introduces significant supply chain vulnerabilities, as any disruptions in China's production or export activities can directly impact the availability and cost of APIs in India.

Recent geopolitical tensions have exacerbated these risks. For instance, the 2026 Strait of Hormuz crisis, which began in late February 2026, led to significant disruptions in global shipping routes, including those critical for transporting raw materials and APIs. The crisis resulted in a sharp decline in maritime transit, with tanker traffic dropping by approximately 70% and over 150 ships anchoring outside the strait to avoid risks. Such disruptions can delay the delivery of essential KSMs to Indian manufacturers, thereby affecting the production and export of capecitabine.

The export market for capecitabine from India is notably concentrated among a few key players. According to TransData Nexus's proprietary trade data, the top five exporters—MANKIND PHARMA LIMITED, ALKEM LABORATORIES LIMITED, MSN LABORATORIES PRIVATE LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, and INTAS PHARMACEUTICALS LIMITED—collectively account for 76.3% of the total export value. MANKIND PHARMA LIMITED alone holds a 35.3% share, amounting to $31.2 million USD. This high level of supplier concentration poses a significant single-source risk; any operational or regulatory issues affecting these leading exporters could disrupt the global supply of capecitabine.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aimed at bolstering domestic API manufacturing and reducing dependency on imports. The PLI scheme focuses on enhancing local capacity, upgrading technology, and decreasing reliance on foreign KSMs. (pharmanow.live) While this initiative is a positive step toward supply chain resilience, its full impact on diversifying capecitabine production and reducing single-source risks remains to be seen.

The global pharmaceutical supply chain is highly susceptible to geopolitical events and shipping disruptions. The 2026 Strait of Hormuz crisis, which began in late February 2026, led to significant disruptions in global shipping routes, including those critical for transporting raw materials and APIs. The crisis resulted in a sharp decline in maritime transit, with tanker traffic dropping by approximately 70% and over 150 ships anchoring outside the strait to avoid risks. Such disruptions can delay the delivery of essential KSMs to Indian manufacturers, thereby affecting the production and export of capecitabine.

Additionally, ongoing tensions between the United States and China have led to trade restrictions and tariffs, further complicating the procurement of KSMs. These geopolitical factors, combined with the high concentration of KSM production in China, amplify the risk of supply chain disruptions for capecitabine.

• Diversify KSM Sourcing: Identify and develop alternative suppliers for KSMs in regions outside of China to reduce dependency and mitigate risks associated with geopolitical tensions.

• Enhance Domestic Production: Leverage the PLI scheme to strengthen domestic manufacturing capabilities for both KSMs and APIs, thereby reducing reliance on imports.

• Strengthen Supplier Relationships: Establish strategic partnerships with multiple suppliers to ensure a more resilient supply chain and reduce single-source dependency.

• Monitor Geopolitical Developments: Implement a robust monitoring system to stay informed about geopolitical events and shipping disruptions that could impact the supply chain, enabling proactive risk management.

• Develop Contingency Plans: Create comprehensive contingency plans, including alternative shipping routes and inventory management strategies, to maintain supply continuity during disruptions.

RISK_LEVEL: HIGH